[
  {
    "ts": null,
    "headline": "FDA Accepts Pfizer (PFE) Vepdegestrant NDA for Breast Cancer, Fast Track Designation Awarded",
    "summary": "Pfizer (PFE) recently announced that the U.S. Food and Drug Administration accepted the New Drug Application for vepdegestrant, offering potential new treatment options for certain breast cancer patients with a PDUFA action date in June 2026. During the last quarter, Pfizer's share price rose by 10%, a movement that stands out against a broader market rise, driven by strong earnings reported across various sectors. Notably, the FDA's acceptance and other positive product-related...",
    "url": "https://finnhub.io/api/news?id=698cc81d4da0690969c1d64f7102d317cce83a3810db6a9754f653b43b173866",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754759730,
      "headline": "FDA Accepts Pfizer (PFE) Vepdegestrant NDA for Breast Cancer, Fast Track Designation Awarded",
      "id": 136292455,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) recently announced that the U.S. Food and Drug Administration accepted the New Drug Application for vepdegestrant, offering potential new treatment options for certain breast cancer patients with a PDUFA action date in June 2026. During the last quarter, Pfizer's share price rose by 10%, a movement that stands out against a broader market rise, driven by strong earnings reported across various sectors. Notably, the FDA's acceptance and other positive product-related...",
      "url": "https://finnhub.io/api/news?id=698cc81d4da0690969c1d64f7102d317cce83a3810db6a9754f653b43b173866"
    }
  }
]